Showing results (1-10 of 31) with videos related to
Sort By:
Pageof 4
Journal of Immunological Methods|October 16, 2002
Selective chemotherapeutic strategies using catalytic antibodies: a common pro-moiety for antibody-directed abzyme prodrug therapyHiroyuki Kakinuma, Ikuo Fujii, Yoshisuke NishiOptics Express|May 13, 2009
CW transillumination imaging by extracting weakly scattered light from strongly diffused lightKazuto Takagi, Hiroyuki Kakinuma, Yuji Kato, et al.Journal of Immunological Methods|December 18, 2004
Directed evolution governed by controlling the molecular recognition between an abzyme and its haptenic transition-state analogNaoko Takahashi-Ando, Hiroyuki Kakinuma, Ikuo Fujii, et al.Journal of Biochemistry|August 22, 2006
Molecular mechanisms of improvement of hydrolytic antibody 6D9 by site-directed mutagenesisNaoko Takahashi-Ando, Kazuko Shimazaki, Hiroyuki Kakinuma, et al.Anesthesia and Analgesia|December 17, 2009
An anatomical basis for blocking of the deep cervical plexus and cervical sympathetic tract using an ultrasound-guided techniqueYosuke Usui, Toshiya Kobayashi, Hiroyuki Kakinuma, et al.Bioorganic & Medicinal Chemistry|January 20, 2007
Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptorDai Nozawa, Taketoshi Okubo, Takaaki Ishii, et al.Bioorganic & Medicinal Chemistry|November 3, 2004
Pyrazole derivatives as new potent and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitorsToshio Nakamura, Hiroyuki Kakinuma, Hideaki Amada, et al.Bioorganic & Medicinal Chemistry Letters|December 31, 2003
Imidazole derivatives as new potent and selective 20-HETE synthase inhibitorsToshio Nakamura, Hiroyuki Kakinuma, Hiroki Umemiya, et al.Journal of Medicinal Chemistry|December 4, 2003
Pyrazole and isoxazole derivatives as new, potent, and selective 20-hydroxy-5,8,11,14-eicosatetraenoic acid synthase inhibitorsToshio Nakamura, Masakazu Sato, Hiroyuki Kakinuma, et al.Bioorganic & Medicinal Chemistry Letters|October 10, 2018
Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetesShoichi Kuroda, Yohei Kobashi, Takahiro Oi, et al.Pageof 4